Navigation Links
HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
Date:1/19/2010

NEW HAVEN, Conn., Jan. 19 /PRNewswire/ -- HistoRx, Inc. announced today that it has appointed Dr. Richard J. Carroll to the newly created position of Vice President, Clinical Research.

Dr. Carroll brings to HistoRx over 20 years of sales, marketing, research, and general management experience in the diagnostic, pharmaceutical and medical device industries. Before joining HistoRx in 2009, he was Vice President of Clinical Research for Cascade Medical Enterprises, a privately-held diagnostics company. Prior to Cascade, Dick held senior positions at Visible Genetics (subsequently acquired by Siemens' Healthcare Diagnostics Group) and Becton Dickinson among other companies.  Dick received his Ph.D. in Immunology and Microbiology from the State University of New York and his B.S. in Biology from LeMoyne College.

"I am excited to be part of HistoRx at this pivotal point in its development and ready to lead the expansion of the company's clinical research program, including the establishment of the HistoRx Clinical Trials Network (HCTN)," said Dr. Carroll.  He continued, "AQUA® technology will be an increasingly important tool in the analysis and validation of clinical biomarkers, as pharmaceutical companies' drug development efforts and the commercialization of new diagnostic products reflect the power of personalized medicine and targeted therapeutics."

Rana K. Gupta, CEO of HistoRx, commented, "Dick's combination of diagnostics industry and product commercialization expertise, and experience with clinical trials, has been of tremendous benefit to the HistoRx management team and will be the keystone of the HistoRx Clinical Trials Network. With Dick's leadership, we will continue to grow our pharmaceutical and biotech relationships and expand our involvement into prospective clinical trials through broader adoption of the AQUA® platform in clinical development."

HistoRx has initiated the HCTN in response to specific interest from pharmaceutical companies wanting to use AQUA technology in prospective Phase II and Phase III trials. For the past five years HistoRx's Pharma Services group has used quantitative assessment of multi-biomarker pathways to find solutions to  scientific problems posed by pharmaceutical companies and oncology cooperative groups involved in drug discovery, preclinical research and clinical development. These solutions have generated crucial information about customer drug candidates such as the metabolic pathways they affect and the patient subgroups most likely to benefit from them. By increasing HistoRx's capacity to run multiple trials, offer additional analytical technologies and expertise, and bring patient populations to the studies, the HistoRx Clinical Trials Network's comprehensive offerings will expand the  customer benefits of these sophisticated tools into late-stage clinical development.

About HistoRx (www.historx.com)

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology. The AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. HistoRx also works with biopharmaceutical companies advance their product pipelines by generating valuable new insights into patient selection, efficacy and safety of therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop proprietary companion diagnostic tests that HistoRx will co-market with its partners' targeted therapeutics.

SOURCE HistoRx, Inc.

RELATED LINKS
http://www.historx.com

'/>"/>

SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. HistoRx Names Bill Sullivan Senior Vice President, Diagnostic Operations
2. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
3. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
4. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
5. The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009
6. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
7. Biomoda Board of Directors Names New Corporate Secretary
8. Ikaria(R) Names New Chairman
9. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
10. Variation Biotechnologies Names Jeff Baxter CEO
11. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):